Vyome Ropes in Ranjan Pai in its board of directors

NEW DELHI, INDIA - Dec 2, 2014 - Vyome Biosciences, an innovation-driven dermatology company focused on hard to treat and refractory dermatology indications, today announced that MD and CEO of Manipal Education & Medical Group, Dr Ranjan Pai, has joined its Board of Directors. Dr Pai’s venture firm Aarin Capital is an investor in Vyome. Dr Richard Buchta, formerly Head of GlaxoSmithKline’s dermatology unit Stiefel Laboratories in Australia, has joined Vyome as Senior Vice-President of R&D.

 Dr Pai is recognized as one of India’s top corporate leaders. As Vyome scales operations and prepares to enter the commercialization phase, his addition adds tremendous strategic experience to the Board. The globalization and expansion of the Manipal Education and Medical Group through his strategic vision is an experience that will serve Vyome in good stead as the Company looks abroad for development and licensing opportunities, said N.Venkat, Co-founder & CEO.

“Vyome is a proving to be a serious innovative play in the life sciences industry, and holds a special place in Aarin’s portfolio. I am personally looking forward to work more closely with the rest of the board, Shiladitya, Venkat and the rest of their team as the Company breaks new ground in markets both in India and abroad,” said Dr Ranjan Pai, Chairman of Manipal Education & Medical Group and Founding Partner at Aarin Capital.

Dr Buchta brings rich specialist experience with numerous patent applications and multiple IND filings in dermatology to Vyome’s senior management team, and this will multiply the Company’s capabilities as we enter the regulatory filing stages for our pharmaceutical programs. Vyome is geared up to press ahead on,” added N. Venkat,

“I am delighted that Dr Pai is getting involved closely with Vyome at this stage - he has a stellar reputation and his extensive experience in the healthcare industry will be of tremendous value to the Company.  Dr Buchta’s engagement will be a tremendous asset too. I am confident that Vyome will go from strength to strength in the coming year,” said Dr. Raghunath Mashelkar, Padma Vibhushan recipient and Chairman of Vyome’s Board of Directors.

About Vyome Biosciences Private Limited

Vyome is a privately-held biopharmaceutical company based in Delhi, India focused on the development of novel therapeutics for hard to treat and refractory dermatology diseases. Vyome has successfully completed clinical research on two products and two lead compounds are in preclinical stage of USFDA program. Vyome is co-founded by Shiladitya Sengupta, Rajesh Gokhale, N. Venkat and Rajeev Mantri and backed by leading venture capital investors Navam Capital, Kalaari Capital, Aarin Capital and Sabre Partners.

Vyome has assembled a world-class management and scientific team, alongside a Board of Directors and Scientific Advisory Board that collectively have a significant track record of conducting acclaimed scientific research, developing breakthrough products and building sustainable businesses.

For Further Information, Please contact

Sowmya Iyer

SI Brand & Communication

Mob 9999561984

Email sibrand.communication@gmail.com

​